CagriSema delivers 25.4% weight loss in early responders: Novo Nordisk

By: IPP Bureau

Last updated : November 17, 2026 5:14 pm



The findings also point to improvements in patients' physical and psychosocial well-being


Novo Nordisk has reported new findings from two post hoc analyses of its Phase 3 REDEFINE 1 trial, showing that adults treated with investigational CagriSema achieved substantial weight loss, with early responders recording an average weight reduction of 25.4% after 68 weeks.
 
The findings also point to improvements in patients' physical and psychosocial well-being, offering further insight into how the investigational combination therapy may affect people living with overweight or obesity.
 
The analyses evaluated CagriSema 2.4 mg / 2.4 mg, a fixed-dose combination of the long-acting amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide.
 
"Obesity is a chronic disease, and people respond to treatment differently and over different timeframes," said Martin Holst Lange, executive vice president, chief scientific officer and head of Research & Development at Novo.
 
"That is why we continue to study the REDEFINE 1 data in greater depth. In this post hoc analysis, most people treated with CagriSema 2.4 mg / 2.4 mg were early responders, meaning they lost at least 5% of their body weight within the first 8 weeks of treatment. Together with the patient-reported physical function results, this research adds to the growing evidence base from the REDEFINE clinical program."
 
The early-response analysis found that 67.8% of participants receiving CagriSema achieved at least 5% weight loss within the first eight weeks of treatment.
 
By week 68, these early responders had recorded an observed mean weight loss of 25.4%. Participants classified as delayed responders achieved an observed mean weight loss of 17.8%.
 
Women were more likely than men to be early responders, with 71.8% of women meeting the early-response threshold compared with 59.5% of delayed responders, according to the analysis.
 
The findings highlight variations in how patients respond to weight-loss treatment and the different timeframes over which meaningful weight reduction may occur.
 
"In clinical practice, it can be hard to know early on how an individual patient will respond to treatment," said W. Timothy Garvey, Department of Nutrition Sciences, University of Alabama at Birmingham, and author of the REDEFINE 1 early response analysis.
 
"This post hoc analysis shows that people treated with CagriSema 2.4 mg / 2.4 mg experienced different weight loss trajectories, including onset of response to treatment. These values are hypothesis-generating, and they are not the basis for changing clinical decision-making."
 
The second analysis examined the impact of treatment on physical and psychosocial functioning, highlighting benefits that go beyond changes on the weighing scale.
 
Researchers used the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT), a validated questionnaire designed to measure how weight affects everyday physical activities, self-esteem and comfort in social situations.
 
At week 68, 73.1% of adults receiving CagriSema reported a meaningful improvement in physical function, compared with 49.1% of participants receiving placebo.
 
The corresponding figures for meaningful improvements in psychosocial function were 69.0% and 42.1%, respectively.
 
The analysis also found that the proportion of participants reporting meaningful improvements in physical function was significantly higher with CagriSema than with placebo from week 8 through week 68.
 
"Obesity goes far beyond the scale; my patients are more concerned with how weight affects their ability to move comfortably and participate confidently in everyday life," said Domenica Rubino, Washington Center for Weight Management and Research, co-author of the REDEFINE 1 physical and psychosocial function analysis.
 
"In this post hoc analysis of REDEFINE 1, 73.1% of people treated with CagriSema 2.4 mg / 2.4 mg reported a meaningful improvement in physical function at week 68, compared with 49.1% of those receiving placebo. Additional post hoc analyses suggest these improvements may begin early in treatment, which warrants further study."
 
The findings also come with a safety consideration, particularly gastrointestinal adverse events.
 
In the REDEFINE 1 trial, discontinuation due to adverse events was reported in 5.9% of participants receiving CagriSema, compared with 3.5% in the placebo group.
 
Gastrointestinal adverse events were reported in 79.6% of participants treated with CagriSema, compared with 39.9% receiving placebo.
 
The most commonly reported gastrointestinal events included nausea (55% versus 12.6%), constipation (30.7% versus 11.6%) and vomiting (26.1% versus 4.1%). These events were mostly transient and mild to moderate in severity.
 
Novo Nordisk filed a New Drug Application with the US Food and Drug Administration in December 2025, seeking approval of CagriSema 2.4 mg / 2.4 mg for weight management.
 
An FDA decision is expected in the fourth quarter of 2026.
 
However, CagriSema is not currently approved for use in the United States. Its safety and efficacy have not been established, and there is no guarantee that the investigational medicine will become commercially available for the uses currently under clinical investigation.

Novo Nordisk CagriSema

First Published : November 17, 2026 12:00 am